Page last updated: 2024-11-13

osu-2s

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

OSU-2S: a nonimmunosuppressive analog of FTY720 with antitumor effects; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	53234284
CHEMBL ID	4171193
SCHEMBL ID	8510221
MeSH ID	M0560441

Synonyms (7)

Synonym
SCHEMBL8510221
1351056-65-9
(s)-2-amino-2-(4-[(6-methylheptyl)-oxy]phenethyl)pentan-1-ol
CHEMBL4171193
HY-117720
osu-2s
CS-0067023

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID1501707	Cell cycle arrest in human HepG2 cells assessed as accumulation at G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 40.4%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501704	Inhibition of Akt Ser473 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501706	Cell cycle arrest in human HepG2 cells assessed as accumulation at sub G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 3%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501708	Cell cycle arrest in human HepG2 cells assessed as accumulation at S phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 24.24%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501700	Induction of PKCdelta cleavage in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501701	Inhibition of Akt Ser473 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501696	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501705	Inhibition of ERK1/2 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501709	Cell cycle arrest in human HepG2 cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 25.6%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501698	Cytotoxicity against human F180 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501710	Cell cycle arrest in human Hep3B p53-deficient cells at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501703	Induction of PKCdelta cleavage in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501695	Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501697	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501717	Inhibition of Akt Thr408 phosphorylation in human Hep3B cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501694	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501699	Induction of apoptosis in human Hep3B cells assessed as increase in caspase3/7 activity at 5 uM after 24 to 48 hrs by Caspase-Glo 3/7 assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501716	Inhibition of Akt Thr408 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
AID1501702	Inhibition of ERK1/2 phosphorylation in human HepG2 cells at 10 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	5 (71.43)	24.3611
2020's	2 (28.57)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.48 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.56 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.48)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fingolimod hydrochloride Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.. fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).	3.03	4	hydrochloride	immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist
sorafenib [no description available]	2.15	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	3.39	6	sphing-4-enine	human metabolite; mouse metabolite

Condition	Relationship Strength	Studies
Hepatocellular Carcinoma [description not available]	7.5	2
Cancer of Liver [description not available]	2.5	2
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.5	2
Liver Neoplasms Tumors or cancer of the LIVER.	2.5	2
Acute Lymphoid Leukemia [description not available]	2.41	1
African Lymphoma [description not available]	2.41	1
Chromosomal Translocation [description not available]	2.41	1
Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	2.41	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	2.41	1
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	2.11	1
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	2.11	1
Canine Diseases [description not available]	2.15	1
B-Cell Lymphoma [description not available]	7.15	1
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	2.15	1

chemdatabank.com